Harrow's earnings show robust growth, but challenges remain. Discover why its valuation and growth targets led to an upgrade ...

This was a phase 4, single-arm, multicenter study during which patients with uncontrolled dry eye who had been on Restasis [cyclosporine 0.05%] for greater than or equal to 3 months were then ...